A major Phase 3 HIV vaccine trial has been stopped after an independent monitoring board concluded that the experimental regimen was safe but did not protect participants from acquiring HIV, closing one of the largest late-stage efforts to develop a broadly effective preventive vaccine against the virus.

The National Institutes of Health said in a January 18 announcement that the HPX3002/HVTN 706 trial, known as Mosaico, enrolled approximately 3,900 volunteers ages 18 to 60 across Europe, North America and South America. A scheduled review by the independent Data and Safety Monitoring Board found no safety problem but determined that the number of HIV infections was equivalent in the vaccine and placebo groups. Based on that finding, the study will be discontinued.

A global vaccine strategy fails its decisive efficacy test

Mosaico began in 2019 as a partnership among Janssen Vaccines & Prevention, the National Institute of Allergy and Infectious Diseases, the HIV Vaccine Trials Network and the U.S. Army Medical Research and Development Command. NIH's original July 2019 trial announcement described the study as a Phase 3 efficacy test designed to determine whether an investigational mosaic vaccine could safely prevent HIV acquisition among men who have sex with men and transgender people.

The vaccine strategy was built around so-called mosaic immunogens, components designed to represent genetic features from multiple HIV subtypes rather than one strain. The goal was to provoke immune responses broad enough to recognize the extraordinary global diversity of HIV. Johnson & Johnson's July 2019 partnership announcement described Mosaico as the first large Phase 3 efficacy study of the company's mosaic-based preventive vaccine approach.

The regimen used four injections over one year of Ad26.Mos4.HIV, which uses a non-disease-causing adenovirus serotype 26 vector to deliver four mosaic immunogens. The final two vaccinations were paired with a bivalent HIV envelope protein formulation containing clade C gp140 and mosaic gp140, with aluminum phosphate as an adjuvant. All study vaccinations were completed by October 2022, according to NIH.

The monitoring board found no efficacy signal

Janssen said in its January 18 trial statement that the independent board reviewed interim data on January 12 and concluded the regimen was not effective compared with placebo. No vaccine-related safety issue prompted the stop. Instead, the critical result was the absence of a difference in HIV acquisition between the two groups.

That distinction is important. A vaccine candidate can produce measurable immune responses and remain acceptably safe without preventing infection. The purpose of an efficacy trial is to establish whether those laboratory and early-stage signals translate into fewer infections under real-world exposure. In Mosaico, they did not.

Participants were not asked to rely on vaccination alone. NIH said every volunteer was offered a comprehensive package of proven prevention tools, including pre-exposure prophylaxis, or PrEP, and people who acquired HIV during the study were referred promptly for treatment. The trial was therefore testing whether vaccination could add protection on top of modern prevention services rather than replacing them.

Mosaico's result follows the failure of a related Janssen regimen in the Phase 2b Imbokodo trial among young women in sub-Saharan Africa. Johnson & Johnson announced in August 2021 that Imbokodo did not provide sufficient protection against HIV infection, although no vaccine-related safety signal was identified. The company's Imbokodo results said the vaccine showed 25.2 percent efficacy, a result that did not meet the threshold for a protective vaccine.

Researchers continued Mosaico because its regimen and study population differed in meaningful ways. The Phase 3 study used a different composition in its final doses and enrolled participants in the Americas and Europe. Johnson & Johnson had also reported earlier clinical data supporting the mosaic approach and said in a 2019 research update that it was advancing Mosaico on the strength of immunogenicity and earlier-stage findings.

The failure of both trials now weighs heavily against this particular vaccine platform as a route to broadly effective HIV prevention. It does not establish that a preventive HIV vaccine is impossible. It shows that generating the kinds of immune responses produced by this regimen was not enough to reduce infections in these populations.

The field confronts HIV's unusual biological difficulty

HIV has frustrated conventional vaccine development for decades because the virus mutates rapidly, exists in enormous genetic diversity and attacks immune cells central to mounting durable protection. Unlike infections for which recovery creates reliable natural immunity, untreated HIV infection does not teach the immune system how to eliminate the virus. Vaccine researchers must therefore create a protective response that natural infection itself does not routinely produce.

IAVI said in a January 19 statement that the absence of efficacy in Mosaico is disappointing but that a safe, effective and broadly accessible vaccine remains an urgent global health priority. The organization emphasized the contribution of the thousands of volunteers and investigators who generated a clear answer about the regimen.

A contemporaneous STAT report described the result as another major setback for a field already marked by difficult late-stage failures. The significance goes beyond one manufacturer's program: Mosaico tested a sophisticated strategy specifically designed to address HIV diversity at Phase 3 scale, and it failed at the endpoint that matters most—preventing infection.

Proven prevention remains essential while vaccine research changes course

The result arrives in a prevention landscape substantially stronger than when the earliest HIV vaccine trials began. PrEP can sharply reduce sexual acquisition risk when taken as prescribed, antiretroviral treatment that maintains an undetectable viral load prevents sexual transmission, condoms remain effective, and post-exposure prophylaxis can reduce risk after a potential exposure. These tools are powerful, but their impact depends on access, uptake, adherence and sustained health-system engagement.

A vaccine could add something fundamentally different: a prevention tool that does not require daily or periodic decisions at the moment of risk and could potentially reach populations with limited access to continuous medication. That is why investigators continue pursuing multiple vaccine strategies even as existing prevention technologies improve.

For Mosaico participants, study teams are now notifying volunteers and planning additional analyses. Researchers will examine immune responses, breakthrough infections and other trial data to understand why the regimen failed and whether any findings can guide future candidates. The absence of an efficacy signal means the trial will not continue simply to accumulate more infections; the scientific question it was designed to answer has been answered.

The outcome is a major disappointment, but it is also a definitive result from a large, international randomized trial. Mosaico shows that the mosaic Ad26-based regimen can be administered without a new safety concern but cannot be relied upon to prevent HIV acquisition. The next challenge for the field is to use that evidence to abandon what did not work quickly enough and redirect effort toward approaches capable of producing stronger, broader and more durable protection.